These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29911761)

  • 1. Antibiotic Exposure in the Community and Resistance Patterns of Escherichia coli Community-Acquired Bloodstream Infection.
    Gottesman BS; Shitrit P; Katzir M; Chowers M
    Isr Med Assoc J; 2018 Jun; 20(6):382-384. PubMed ID: 29911761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study.
    Mehl A; Åsvold BO; Kümmel A; Lydersen S; Paulsen J; Haugan I; Solligård E; Damås JK; Harthug S; Edna TH
    BMC Infect Dis; 2017 Feb; 17(1):116. PubMed ID: 28148226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and quinolone resistance of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in 6 communities and 2 physical examination center populations in Shanghai, China.
    Ni Q; Tian Y; Zhang L; Jiang C; Dong D; Li Z; Mao E; Peng Y
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):428-433. PubMed ID: 27681363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
    Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa.
    Malande OO; Nuttall J; Pillay V; Bamford C; Eley B
    PLoS One; 2019; 14(9):e0222675. PubMed ID: 31550295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does HIV status affect the aetiology, bacterial resistance patterns and recommended empiric antibiotic treatment in adult patients with bloodstream infection in Cambodia?
    Phe T; Vlieghe E; Reid T; Harries AD; Lim K; Thai S; De Smet B; Veng C; Kham C; Ieng S; van Griensven J; Jacobs J
    Trop Med Int Health; 2013 Apr; 18(4):485-94. PubMed ID: 23294446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of high mortality with extended-spectrum β-lactamase (ESBL) positive cultures in community acquired infections.
    Ray S; Anand D; Purwar S; Samanta A; Upadhye KV; Gupta P; Dhar D
    J Crit Care; 2018 Apr; 44():255-260. PubMed ID: 29220754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis.
    Bedoin M; Cazorla C; Lucht F; Berthelot P; Boyer M; Carricajo A; Guérin T; Viallon A
    Med Mal Infect; 2014 May; 44(5):206-16. PubMed ID: 24794820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting.
    Gottesman BS; Carmeli Y; Shitrit P; Chowers M
    Clin Infect Dis; 2009 Sep; 49(6):869-75. PubMed ID: 19686074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
    Park SH; Choi SM; Lee DG; Kim J; Choi JH; Kim SH; Kwon JC; Yoo JH
    Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bloodstream infections in community hospitals in the 21st century: a multicenter cohort study.
    Anderson DJ; Moehring RW; Sloane R; Schmader KE; Weber DJ; Fowler VG; Smathers E; Sexton DJ
    PLoS One; 2014; 9(3):e91713. PubMed ID: 24643200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
    Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
    Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
    Tumbarello M; Sali M; Trecarichi EM; Leone F; Rossi M; Fiori B; De Pascale G; D'Inzeo T; Sanguinetti M; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3244-52. PubMed ID: 18591273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant Escherichia coli bacteremia at a medical center in Taiwan.
    Lin WP; Huang YS; Wang JT; Chen YC; Chang SC
    BMC Infect Dis; 2019 Mar; 19(1):245. PubMed ID: 30866828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.